Day: September 26, 2018

Aduro Biotech to Present at Two Investor Conferences in October

From Startup Aduro Biotech Link to Full Article: BERKELEY, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the following upcoming investor conferences: Cantor Fitzgerald 2018 Global Healthcare Conference in

Neon Therapeutics to Present at Upcoming Investor Conferences in October

From Startup Neon Therapeutics Link to Full Article: CAMBRIDGE, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) — Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, President and Chief Executive Officer of Neon, will present at the following upcoming investor conferences: Ladenburg Thalmann 2018

Sophiris Bio to Present at the Cantor Global Healthcare Conference

From Startup Sophiris Bio Link to Full Article: http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-present-cantor-global-healthcare-conference SAN DIEGO and VANCOUVER, British Columbia, Sept. 25, 2018 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced

Kyorin Receives Approval from Japan’s Ministry of Health, Labour and Welfare for Vibegron for Overactive Bladder

From Startup Urovant Link to Full Article: https://urovant.com/2018/09/25/kyorin-receives-approval-from-japans-ministry-of-health-labour-and-welfare-for-vibegron-for-overactive-bladder/ Kyorin secures first commercial approval for vibegron Vibegron will be a new treatment option in Japan, where an estimated 10.4 million people suffer from overactive bladder symptoms defined as the sudden urge to urinate, frequent urination and urge incontinence BASEL, Switzerland and IRVINE, Calif., Sept.

Eidos Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology

From Startup Eidos Therapeutics Link to Full Article: http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-present-leerink-partners-roundtable-series SAN FRANCISCO, Sept. 25, 2018 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology on Tuesday, October 2, 2018 at 3:30 p.m.

Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology

From Startup Synlogic Tx Link to Full Article: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 25, 2018– Synlogic(Nasdaq:SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the Leerink Partners Roundtable Series on Rare Diseases and Oncology at 11:30